Francais
info@saveyourskin.ca

immunotherapy

Introducing “Redefining Cancer Treatment” by Merck

We are excited to announce that one of our partners, Merck, has launched an informative new website dedicated to educating the public about immuno-oncology. 

“Redefining Cancer Treatment” is an apt title for the topic: what is cancer immunotherapy, and how does it work, exactly? These questions are answered in a few pages and a downloadable infographic, all in language that is easy for patients and their caregivers to understand.

RedefiningCancerTreatment.ca discusses two main cancer types which are showing response to immuno-oncology treatments – Melanoma skin cancer, and Non-small cell lung cancer. It also has a page which lists all of the treatments currently available in Canada for the treatment of these diseases.  This example of collaboration and transparency is an excellent representation of the innovative attitude it takes for work in a field such as this to develop and, ultimately, save lives.

To view the website click here: RedefiningCancerTreatment.ca     |    To view the two-page infographic please click here: Cancer Treatment at a Glance

Merck also has an interactive website listing enrolling clinical trials for their treatments, in cancer and in other indications.  Click HERE to view the site and search for your disease type: Merck Clinical Trials

 

We are grateful that Merck has taken this initiative to better support patients, and we applaud their efforts.  Redefining Cancer Treatment is a valuable resource and we hope to share this website far and wide, help to increase patients’ awareness of immuno-oncology and the options they may have when faced by melanoma skin cancer.

Read more

SYSF Survey! Melanoma Treatments for Adjuvant Patients

Save Your Skin has the opportunity to submit patient feedback to the pCODR process for the two treatments coming to the Adjuvant setting for Melanoma patients in Canada.  To learn more about the drug approval process and our involvement as a patient representation group, please visit our page: “Let’s Chat: Patient Submissions and Discussion

We believe the ability of stage I, II, and II melanoma patients to receive innovative treatments is key to survival, and to the reduction of progression to stage IV disease.

To inform our upcoming submission, we have created a short survey and request that any and all patients touched by melanoma complete the survey to have their voices heard.  This survey is open globally, to all stage melanoma patients at any point in their journey; but we request that IF you are a metastatic patient taking the survey, but were diagnosed at stage 1, 2 or 3 could you please take some time to remember back to those days and fill in what you can in the survey pertaining to those times.  Were you offered a treatment, were you advised to “wait and watch” and what were those times like for you and your family.

This anonymous survey is now closed.  We thank all who shared their time and experience in responding to the survey.  Stay tuned for news of our completed submission to pCODR and INESSS.

If you have any questions or feedback about this topic or the survey itself, please email info@saveyourskin.ca

Thank you! 

Read more

Calling all STAGE I, II & III MELANOMA PATIENTS in Canada!

Please participate in this survey regarding preferences for adjuvant treatment of melanoma in Canada. The ANONYMOUS SURVEY will require approximately 30 minutes to complete.

Sponsored by Novartis, the information in this study may be included in research publications and submissions to agencies that evaluate and make recommendations regarding reimbursement of treatments for patients in Canada.

To participate, please CLICK HERE. The survey will remain open for completion until midnight (EST) on Friday, August 17, 2018.

 

In order to qualify for participation, you must (1) currently reside in Canada, (2) have a current diagnosis of local or regional melanoma (Stage I, II, or III), and (3) be at least 18 years of age. Individuals who reside outside of Canada, do not have melanoma or currently have metastatic melanoma (Stage IV), or are younger than 18 years of age are not eligible to participate.

If you have any questions, you may contact the study manager or the sponsor directly using the contact information below: 

Study Manager Study Sponsor

Daniel Stellato, BS

Research Analyst

Policy Analysis Inc. (PAI)

Four Davis Court

Brookline, MA 02445

USA

Phone: 617-232-4400

Email: dsetllato@pai2.com

 

Marroon Thabane, PhD

Manager, Health Economics and Outcomes Research

Oncology Business Unit

Novartis Pharmaceuticals

385 Bouchard Blvd.

Dorval, Quebec H9S 1A9  CANADA

Phone: 905-512-3755

Email: marroon.thabane@novartis.com

 

About Policy Analysis Inc. (PAI)

PAI is a health economics and outcomes research (HEOR) organization providing services to the global biopharmaceutical industry located in Brookline, Massachusetts, USA (https://www.pai2.com).

About Novartis

Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide (https://www.novartis.ca/en).

Read more

Introducing BMS Study Connect

At a recent meeting in Montreal with the Bristol-Myers Squibb Canada (BMS) team, we found a fantastic new resource they have launched to improve patient communication and access to BMS clinical trials.

Their website, “BMS Study Connect” is a user-friendly platform to allow patients and caregivers to easily search for new, open, upcoming, or past clinical trials for BMS products in any health indication.  It provides background information on diseases treated by their pharmaceuticals, plus has a search bar and links to more information for several diseases including fibrosis, cardiovascular and autoimmune diseases, plus several types of cancer including head & neck cancer, blood, gastrointestinal, genitourinary, and lung cancers as well as melanoma.

BMS has done a lot of research in melanoma over the years and is credited with the creation of ipilimumab (Yervoy) which has greatly contributed to the shift toward an increase in melanoma survivorship.  Currently their ipilimumab-nivolumab combination treatment is in great demand, and they are working on yet other possibilities for the treatment of melanoma.  On BMS Study Connect, patients can search for any open trials involving these treatments or others, and can even answer a few qualifying questions to figure out if they may be eligible to participate in a new trial.

If a patient finds a clinical trial they would like to learn more about, they can print out the details from BMS Study Connect and take it to their medical team to see if and where they may be able to participate. By clicking on the “Pre-Screen Now” button patients can enter their details as applicable and find more information.  Some of the information on BMS Study Connect is sourced from the reputable clinicaltrials.gov website, which adds the ability to connect patients with applicable trials outside of BMS.

BMS Study Connect allows for patients to better understand their clinical trial options and experience, and allows them to communicate with BMS in a way that makes the situation more personal.  BMS genuinely cares about the patient experience in their clinical trials, and is making a great effort to show that through this online presence.

There is also the option for patients to connect with other patients to discuss their trials or topics related to their condition.  By clicking on the word “Community” at the top of the site, users will be re-directed to the secure and free website inspire.com, and invited to join the BMS Clinical Trial Support Community in which they can chat with other patients and share experiences.

At this time the community is overseen by representatives from the United States, but it is open globally, and there is Canadian participation.  It is beneficial to draw from the experiences of others even in the States at this point, as their population of BMS-product-recipients is larger in general, therefore there is more information to be gleaned from fellow trial participants.

We are grateful that BMS has taken this initiative to better support patients, and we applaud their efforts.  BMS Study Connect is a valuable resource and we hope to share this website far and wide, help to increase patient access to clinical trials and help them to understand their options and better navigate the clinical trial process and follow-up.  Check it out here:  BMS Study Connect

Read more

SYSF Attends ESMO 2017 Congress

September 8-12, 2017, Kathy Barnard attended the ESMO 2017 Congress, European Society for Medical Oncology, in Madrid Spain.  In partnership with the European Association for Cancer Research, ESMO brought cancer researchers and clinicians together to enable collaboration and the exchange of ideas, from the laboratory to the bedside and back. This exciting partnership creates a unique cancer congress in Europe with huge scientific reach and the true potential to improve the lives of cancer patients.

With her, Kathy brought home the latest in news about melanoma and other skin cancers, as summarized in this report: ESMO 2017 Congress – Melanoma Highlights.

View or download the report HERE for details about the following:

Plenary Sessions
Adjuvant dabrafenib plus trametinib significantly lowers risk of death in stage III BRAF V600–mutated melanoma
BRIM8 data shows benefit with adjuvant vemurafenib in resected BRAFV600 positive melanoma
Nivolumab bests ipilimumab as adjuvant therapy in resected melanoma

Article from ESMO Daily Reporter
Practice-changing phase III data in melanoma patients cause excitement at a Presidential Symposium

Links to Press Releases
ESMO 2017 Press Release: Combination Targeted Adjuvant Therapy Doubles Relapse-free Survival in Stage III Melanoma
ESMO 2017 Press Release: Adjuvant Nivolumab Superior to Ipilimumab in Surgically Resected Stage III/IV Melanoma

Poster Submissions

Read more

Danika’s Story: I was 19 years old when I had my first contact with melanoma

 – Guest Blog Post by Danika 
IMG_3071

I was 19 years old when I had my first contact with melanoma. I had a beauty mark on my back and it began to grow bigger and had a reddish hue.

A dermatologist did a biopsy and I had the diagnosis on December 28 2011; I was 19 and I had a malignant melanoma, the most serious form of skin cancer. I had a PET scan and a lymphoscintigraphy. Fortunately, at that time, I had no metastases. I had an operation to remove the beauty mark and the skin below and I was told that everything was fine. I only kept a scar shaped like a bird as a souvenir.

However, two years later, I was stage four melanoma.
The previous weeks, some lumps grew on my abdomen, my chest, and even my face. So we did biopsies and it was subcutaneous metastases. A PET scan later, I learned that I also had metastases to the liver, lungs and bones. At that time, I knew it was serious, but I had no idea how my life was about to change.

I was quickly supported by my hospital, the CHUM Notre-Dame, who proposed me to be part of a research protocol. I started taking tablets of « LGX818 », it was so new that they did not even have an official name yet. They were anti-BRAF drugs, since I had the BRAF mutation. One of the worst side effects that I had was peripheral neuropathy. It felt like having electrical shocks in my body. Then came the first scans results ; the treatment was working since some metastases decreased volume and no new one had appeared. Muscle pain, nerve, joint, skin problems, all of it was now worth it.

However, a few weeks after starting treatment, a new side effect appeared. In medical parlance, it is called “alopecia”. More simply, it means hair loss. Of course when you think chemotherapy you think hair loss, but my treatment was not supposed to do that, so I wasn’t prepared. In a few weeks I had to witness the loss of at least 50% of my hair, and believe me, I had a lot of hair! I found some in my bed, in the shower, on the couch, carpet, everywhere … I couldn’t take it anymore so I asked my mother to shave all of it. I anticipated this moment and yet none of us has shed tears. To my surprise, I was not so bad without hair. I still decided to wear a wig to school, to avoid passing from one extreme to the other and catch the eye of everyone.

After nearly 8 months of treatments, I had an appointment with my oncologist and I felt that something was wrong. Indeed, the latest scan results showed new lesions. My body got used to the medication and became resistant to it. We had to change treatment. New drugs were just emerging in Canada and were offering promising results. However, we must pass through a conventional chemotherapy before gaining access to the other treatments. These new treatments cost a lot of money so you have to « try everything » before.

A week later, it was time for that chemotherapy called Dacarbazine. It was the first time I found myself in these kinds of rooms, you know the rooms where there are several chairs next to each other, and on which are literally plugged patients. And of course, most patients are older and the majority have no hair. The image gives a shock. However, once installed in my chair, I noticed that the atmosphere was not so bad.

The next days were very difficult. I had nausea, fatigue and flu-like symptoms. I was going to school when my condition would let me. My next dose was scheduled three weeks later but it never took place. Bumps had appeared on my body; Dacarbazine wasn’t working on me at all. At least, now I had access to the new treatment. Again, I had to change course.

The new treatment, Yervoy, was actually immunotherapy, which rely on our natural immune system to destroy cancer cells, that’s the essence of immunotherapy. A few days later, on May 14, the day before my birthday, I found myself once again in the treatment room, but this time with another liquid pouring into my veins.

The first shot was held pretty well and I could finish my session. In addition, hair began to appear on my skull. However, bad news came back; I started to feel horrible abdominal pain. I even felt my tumors growing back. On the abdomen, I had a big lump like a cherry, right under my skin. So I felt it constantly.

I went to the hospital and the on-call oncologist decided to do the scans and all the tests right then. She came back several hours later with the results … Just by the look on his face, his way of coming to me, I felt it was bad. He sat on my bed, took my hand and said: “The news are not good, tumors got bigger, especially the one on the liver and it’s probably what’s causing your pain. ”

So … we turned to a fourth type of treatment in one year. I was exhausted. This was the latest treatment available in Canada for melanoma. It was still immunotherapy, but called Pembrolizumab (Keytruda).

The first Keytruda treatment went well. A few days later, the pain seemed to lessen a bit. I got to do some activities, saw some friends, etc. A few weeks later, the scan results finally brought some good news; after only 3 shots, metastases were reduced by approximately 50%! And I had almost no side effects; only fatigue the days following treatment, as well as vitiligo that appeared on my body.

So here I am, May 2016, I just turned 24 years two days ago, and my current treatment, pembrolizumab, is finally working. I had 13 shots so far and I will continue for at least another year. I hope that future scans will be even better than the last ones. I got back to school, my hair grew back and I can finally start to enjoy life again!

Those last two years were a rollercoaster of emotions. We all have the right, at times, to be afraid and desperate. The important thing is to get up and always keep in the back of our mind the hope to believe that everything will be fine.

Read more

Immunotherapy Fights Deadly Cancer- Meloney and Kathy Share Their Stories

IMMUNOTHERAPY FIGHTS DEADLY CANCER

|

spectrumadvisors-featimg-mole

Immunotherapy is the latest advance in the way cancer is treated, using the body’s own immune system to fight otherwise deadly disease. Meloney Edghill knows it can work.

spectrumadvisor-advimg-meloneyandson

Meloney also knows what the mother of a young child thinks about when told she has terminal cancer. She chokes back tears remembering: “I was worried it would kill me before my 4-year-old son would have any memories of me. I didn’t want him growing up and not remembering me at all.”

That was in April 2006. The fact that Meloney is still here to tell her story – and watch her son grow to a teenager – is thanks to the development of the newest form of cancer treatment, immunotherapy. Unlike the traditional approaches to cancer treatment – surgery, radiation, chemotherapy and targeted therapy – immunotherapies are drugs that release the natural brakes on the body’s own immune system so it can fight and kill the cancer cells.

In April 2006, the young mother was living in Edmonton and had a lump growing on the front of her shoulder. When she went to the doctor to check it out, it was too late.  She was diagnosed with metastatic melanoma, the most serious form of skin cancer.  It accounts for just 8 per cent of skin cancer cases, but is responsible for 70 per cent of deaths from the disease.

When she was first told she had melanoma, Meloney didn’t realize the implications. “I initially thought they would just cut it out and everything would sort of be OK after that,” she recalls. “We found out very fast that it was not that simple and in fact there were very few options.  We were devastated.”

At the time, the average life expectancy for someone with Meloney’s diagnosis was about six to nine months. That October, she enrolled in a trial of a new melanoma immunotherapy that was in an early study.

In January 2007, when tested to see how she had responded, Meloney was taken by surprise. “All of my cancer was just about gone after that,” she says. “It was unbelievable to my doctors and nurses that something had worked that well and that quickly.” According to her doctor, today Meloney is cancer free and her son, who is a now a teenager, has grown up with his mother at his side.

Meloney’s experience with the treatment is not shared by all melanoma patients, but the immunotherapy she took has shown good results in studies. It has been approved for use in Canada and other countries and is the first-ever treatment shown in clinical studies to improve survival of patients with metastatic melanoma.  Ongoing research continues to give new hope to those diagnosed with the disease.

Today there are even newer immunotherapies available.  The latest ones work in different ways to stimulate the immune system, shutting off a different one of the “checkpoint inhibitors” which act as natural brakes on the immune system and prevent it acting against cancer cells. These newer immunotherapies are also being studied with promising results in combination with the older drugs in melanoma and as potential treatments for a wide variety of other cancers and are showing promising results.

“Immunotherapy has completely transformed the way advanced melanoma is treated.  Just a few years ago patients who were diagnosed were desperate and many were told to ‘get their affairs in order’. In just a short period this cancer went from being defined as a deadly disease to a cancer that patients may be able to survive,” says Kathy Barnard, Founder and President of the Save Your Skin Foundation, a melanoma patient support organization that also aims to educate the public on the importance of protecting the skin from the sun’s harmful ultraviolet rays, a major risk factor for skin cancer.

“What’s even more exciting is that there is ongoing research with immunotherapy which means more treatments are available to patients to give them options.  Can you imagine?  Advanced melanoma patients have treatment options to survive?  I never dreamed this would happen in my lifetime. I’m here today witnessing history being made.  In fact, I’m living proof of it,” Kathy adds. She herself is a melanoma survivor, another beneficiary of the same treatment that helped Meloney.  Kathy has since devoted herself to helping others and educating about the disease.

For more information please visit imlivingproof.ca

Copyright 2015 ZoomerMedia Limited

Read more